news/
181 pages · Updated 2026-10-15
Pages
- Inventiva H1 2026 Earnings Call: Complete Transcript
- 15364304598868992
- Transcript: Niagen Bioscience Q2 2026 Earnings Conference Call
- Beltic Emerges from Stealth to Secure Autonomous Agent Transactions at Scale
- Transcript: Riocan REIT Q2 2026 Earnings Conference Call
- International Seaways (INSW) Q2 2026 Earnings Call
- HONDA CENTER KICKS OFF 2026-27 SEASON WITH EXCITING NHL SCHEDULE, HIGHLY ANTICIPATED CONCERTS, NEW FOOD & BEVERAGE, AND CONTINUED ARENA UPGRADES AHEAD OF OCVIBE OPENING SPRING 2027
- Co-Diagnostics Reports Second Quarter 2026 Financial Results
- The Galien Foundation Announces Nominees for the Inaugural 2026 Prix Galien Patient First Award in Honor of Michael J. Fox
- IPO Foresight | After submitting Hong Kong stocks twice, can Jingxin Pharmaceutical successfully achieve AH double listing?
- Transcript: Sotera Health Q2 2026 Earnings Conference Call
- SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement
- Tyson Foods CEO-Elect Schomburger Buys $1 Million in Stock. What Is His Confidence Telling Investors?
- Saber-Hightower, Rafferty Real Estate, and Eagle Realty Group Break Ground on The Ibex at Ridge Hill, a $140 Million Residential Tower in Yonkers
- GRAIL (GRAL) Stock Sinks As Cash Burn Drowns Galleri Growth
- Transcript: United Rentals Q2 2026 Earnings Conference Call
- PM360 2026 Trailblazer Awards Winners Announced: Top Companies, Marketers, CEOs, Products, and Initiatives Honored at Gala, Sept. 29th
- Advanced Micro Devices vs. Qualcomm: Which Technology Stock Is a Better Buy in 2026?
- Japanese Growth Stocks To Watch In October 2026
- Civitas Closes $104 Million Senior Loan for 164-Unit Class A Multifamily Community in Colorado's Vail Valley
- Jianfeng Group announced that Zhejiang Jianfeng Yien Biotechnology Co., Ltd., a holding subsidiary of the wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The notification numbers are 2025LP03024, 2025LP03025, and 2025LP03026. The drug name is JFAN-1001 mesylate capsules. The indication is locally advanced or metastatic non-squamous non-small cell lung cancer with a positive secondary mutation of EGFR-T790M.
- Your Reno Works Pte Ltd Named Distinguished Brand of the Year, Celebrating Nearly a Decade of Trusted Renovation Excellence
- Arixa Capital Closes $74.8 Million Construction Loan for Townhome Community in Flagstaff, Arizona
- Aimbridge Hospitality named future operator of Portman’s 700-key Cincinnati Downtown Marriott development
- THE NELL NEW YORK UNVEILS DESIGN VISION BY ROCKWELL GROUP AND PIERRE & CO.
- OEM International (OM:OEM B) Faces A Board Change As Valuation Questions Build
- Stryker (SYK) Q2 2026 Earnings Call Transcript
- IPO News | Jingxin Pharmaceutical (002020.SZ) once again submitted the Hong Kong Stock Exchange successfully launched the Class 1 innovative drug didacinil
- Dallas Apartment Developers Eye City Loan
- 9537098999874560
- Kexuan Power Holdings (00476) plans to issue a total of 99 million shares at a premium of about 4.8% to raise about HK$65.1 million
- Development Team Pursuing 376-Unit Tempe Apartment Venture
- Sanctions Allegations Could Be A Big Test For Raiffeisen Bank International Stock
- 3 US Rate Driven Yield Stocks Investors May Be Missing
- Harmony Biosciences presents Phase 3 HBS-301 trial data in narcolepsy, idiopathic hypersomnia at European Narcolepsy Days
- Seresco launches EUR 20 million commercial paper programme on MARF
- Trinsic Building Apartments at Site of Notorious Wheat Ridge Hotel
- Lawmakers Reject Exton Square Redevelopment, Developer ARD Plans To Sue
- Endura Starts Work on 324-Unit Boerne Apartment Community
- Is Rubrik (RBRK) Quietly Redefining Enterprise AI Resilience With Its Wipro Partnership?
- Capstone Development to Build Student Housing at the University of Virginia
- Starting in 2026, Apple plans to break the long-standing unified fall release rhythm and switch to the strategy of launching new iPhone products twice a year. This is the biggest change in the product release model in more than 10 years. According to Mark Gurman's latest report, Apple will schedule the flagship model to be released in September every year, while the entry-level and mid-range models will be launched in the spring of the following year. The new pace will begin in the fall of 2026, when Apple will release three to four high-end models, including the iPhone 18 Pro, iPhone 18 Pro Max, the first folding screen iPhone, and the iPhone Air, which is expected to be updated. The basic version of the iPhone 18 and the iPhone 18e for the larger market will be launched in the spring of 2027, and a total of five to six new products will be released every year during the two seasons. An important background to this adjustment is intense global smartphone competition, particularly pressure from Chinese rivals. Manufacturers such as Huawei and Xiaomi release flagship models in batches throughout the year, and Apple usually lacks new products in the first half of the year, leading to a so-called “empty marketing window”, which is being taken over by competitors. With two releases from March to April and September, Apple hopes to close the gap with the Android camp in the first half of the year. The shift in strategy also responds to revenue distribution issues. Currently, iPhones contribute about 50% to 55% of Apple's overall revenue, and demand is highly concentrated after new products are launched in the fall. Through quarterly releases, Apple hopes to smooth out sales fluctuations and make the pace of revenue more balanced throughout the year. The iPhone 17 series released in 2025 will be the last unified product to be unveiled in September. Apple recorded iPhone revenue of 49 billion US dollars in the most recent quarter ending in September, setting a record for the same period.
- AI Small Cap Stocks Retail Investors Are Watching For Growth
- Full Transcript: Autodesk Q2 2027 Earnings Call
- Anchorage Commodities Investment Business to Become Moorstone
- Baiyunshan (00874): Tianxin Pharmaceutical received the “Drug Registration Certificate” for irbesartan hydrochlorothiazide tablets approved and issued by the State Drug Administration
- Boan Biotech (06955): BA2201 (TL1A/IL-23) clinical trial application accepted by CDE
- 13481794658305024
- Top Wall Street Forecasters Revamp Prologis Expectations Ahead Of Q3 Earnings
- Lument’s Vic Clark Provides Preview on How Deals Are Getting Done for Upcoming Texas Multifamily 2026
- Marcus & Millichap brokers sale of 71-room Holiday Inn Express & Suites in Temple, Texas
- Townhome Project Slated for Transforming Denver Mall
- Coherent, Lumentum, Ciena Stocks Fall After Corning Earnings Trigger Sector Selloff
- Micron (MU) Q4 2026 Earnings Call Transcript
- On September 9, local time, the Iraqi Ministry of Transport issued a statement saying that at 5:30 a.m. on the same day, an oil tanker flying the Panamanian flag and used to transport fuel was hit by an object of unknown origin in Iraqi territorial waters, and the hull was damaged. There were no injuries or cargo leaks as a result of the incident. The statement said that after the incident, relevant Iraqi safety, maritime and other departments immediately took preventive measures, isolated the ship and continuously monitored the ship, and carried out on-site monitoring of the surrounding waters to confirm whether there were fuel leaks, other damage, and risks that could affect navigation safety and the marine environment. The Iraqi Ministry of Transport said that relevant departments are investigating the details of the incident and verifying the source of the attack and the cause of the incident.
- 12621466711344128
- First Canadian Graphite Completes Phase I Exploration on Zone 13 Discovery and Expands Lands Package
- Is Advantest (TSE:6857) Fully Valued As Its New DFT Platform Draws Investor Attention?
- Affinius Capital Provides $76M in Acquisition Financing for Ohio Distribution Center
- Hainan Mining (601969.SH) released semi-annual results, with net profit of 281 million yuan to mother, a year-on-year decrease of 30.36%
- AutoZone (AZO) Stock Looks Pricey On Earnings Yet Firm On Cash Flow
- GMH Communities and Invesco Real Estate Acquire Student Housing Portfolio Steps from Purdue University
- Nasdaq Reports September 2026 Volumes and 3Q26 Statistics
- Private Corner launches co-investment fund after €60 million raise for predecessor
- Pavilion REIT: EPF lifts stake to 12.607% after acquiring 2,280,000 units
- Wanhua Chemical announced that the 1.2 million tons/year ethylene phase II plant in Yantai Industrial Park will stop production and maintenance on October 10, 2026. The maintenance is expected to take about 60 days; during this period, the ethylene phase I plant will produce normally. This discontinuation of production is a routine inspection within the annual plan and will not have a significant impact on the company's production and operation.
- The Stock Market Is Repeating a Pattern Not Seen Since the Dot-Com Bubble. History Says Investors Should Make This 1 Move Right Now.
- SailPoint (SAIL) Q2 2027 Earnings Call Transcript
- CEO & Director of Property Franchise Group Gareth Samples Buys 1.6% More Shares
- Is MP Materials (MP) Undervalued As It Expands Rare Earth And Magnet Supply Deals?
- Former Everett Hotel Set for Conversion Into Apartments
- As of October 1, 2026, SPDR Gold Trust, the world's largest gold ETF, had holdings of 1056.55 tons, an increase of 0.85 tons over the previous trading day.
- Transcript: CarMax Q2 2027 Earnings Conference Call
- Marwood Group Announces Strategic Investment from funds managed by Lee Equity Partners, LLC and Appointment of Chris Librizzi as CEO
- Silverstone Development, Kimpton Hotels to Revamp Historic Indianapolis Building
- 13477984430654464
- China's semiconductor equipment investment boom is expected to continue! Damo: Wafer manufacturing equipment spending is expected to continue to grow in 2027 and 2028, and the localization process may be further accelerated
- Affinius Capital Originates $95M Construction Loan for Oregon State University Student Housing
- Developer Targeting I-40/I-85 Interchange for Apartments, Convenience Store
- JLL Facilitates Equity Placement for Residential Property in Kansas
- Two Merritt 7 Office Properties Set for Residential Conversion
- Changes in Hong Kong stocks | Shimao Group (00813) rose more than 30% at the end of the session and rose nearly 60% in a month. The company said it would oppose the winding-up petition
- MetLife (MET) Group Benefits Jumped In Q2, Is It Still Below Fair Value?
- VANTORA: AS PART OF INVESTMENT, TODD MACLEAN, DANIELLE WALDMAN & ANNIE CORY WILL JOIN CO'S BOARD
- 3 California Tech Stocks With Real Exposure To Digital Growth
- Jimin Health announced that the drug DB006 oncolytic adenovirus injection from the holding subsidiary Hainan Jimin Boao International Hospital Co., Ltd. has been officially accepted by the Drug Evaluation Center of the State Drug Administration for Phase I clinical research. This drug is a gene therapy drug for the treatment of advanced malignant solid tumors. Currently, 5 oncolytic virus drugs have been approved and marketed globally, and about 7 drugs in the domestic market are in phase I/II clinical trials. The company will promptly disclose the progress of the project and alert investors to the risks.
- JR West, Resona Group form capital and business alliance via Kansai Mirai Bank stake transfer
- 12326235348498432
- Investor Duo Funds 200-Unit Peoria Apartment Community
- Work Underway on New $116M Sedona Resort
- Get Nice Securities resumes electronic trading after cyberattack disrupts systems
- Avatar Bridge Loan Finances Acquisition of Historic Providence Hotel
- Wood Partners Breaks Ground on All-Electric Community Near Boston
- According to Mizuho analysts, Lyondell Basell shut down its Houston refinery designed to process heavy Venezuelan crude oil less than a year ago, but as the US seeks control of Venezuela's crude oil reserves, the company may find it more valuable to sell the plant to another company. Analysts pointed out that Lyondell Basell had discussed using some of the refinery's assets to turn waste plastic into oil or convert it into a clean hydrogen energy base, “but recycled plastics and clean hydrogen energy projects are currently being delayed.” Analysts believe that “this site may be of greater value to another company willing to reinvest and restart as a refinery.” Although the site is over 100 years old, adding to the complexity of the transaction, analysts say Lyondell Basell may be an active seller.
- Wealth Enhancement to Acquire Wealth Advocates, a Hybrid RIA with Over $476 Million in Client Assets
- Century Communities’ Century Living opens leasing at 327-unit Onyx luxury apartments in Lone Tree, Colorado
- Sensor Tower: Dick Interactive “Whiteout Survival” takes the top spot in the mobile game revenue list in December 2025
- Phoenix Equity Partners sells UK cybersecurity firm Logiq to IBM
- Inland to Develop Apartments near Mayo Clinic in Rochester
- Stifel Reports August 2026 Operating Data
- US Stock Outlook | Futures of the three major stock indexes rose sharply, earnings season began
- New Reasons for Travelers to Stay, Play and Explore in Daytona Beach
- Lepu Medical announced that Shanghai Minwei Biotechnology Co., Ltd., a holding subsidiary of the company, will license MWN105 injections with independent intellectual property rights to Sidera Bio Aps in Denmark for a fee. , the Danish company Sidera will receive exclusive rights to develop and commercialize on a global scale other than Greater China. In return, Shanghai Minwei Biotech will acquire 9.99% of the shares in the Danish company Sidera and will obtain licensing fees for MWN105 injections from Sidera in Denmark. The licensed product MWN105 injection is a GLP-1/GIP/FGF21 receptor triple agonist independently developed by Shanghai Minwei Biotech. It is currently undergoing clinical trials in China.
- HUAWEI AppGallery Wins Leading App Store Experience at Mobile Games Awards 2026
- Titan Hospitality Announces Grand Opening of The Blackwall Barn & Lodge in Wilmington, Delaware
- Confluence Financial Partners Announces Strategic Partnership with Constellation Wealth Capital
- Sandy Springs Okays Incentives for Mall Redevelopment
- Sonos Stock Is Watching An AI Audio OS Rollout And New Flagship Devices
- Lennar Breaks Ground on the Residential Homes at Broadcast District, a Walkable Mixed-Use Community in Wyomissing, PA
- $76M in Capital Secured by JLL for Minneapolis MF Development
- Three Days Left Until PHC Holdings Corporation (TSE:6523) Trades Ex-Dividend
- We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully
- Viewpoint School and Berkeley Hall School to Merge, Transforming the Landscape of Independent School Education in Los Angeles
- BIG 4 Alliance Partners with Supply Chain Federation, CREDA SoCal
- Webull Expands Cloud MCP to Enable AI-Powered Trading Without Coding or Installation
- 13498837593621504
- HiCisco (002653.SZ) obtained clinical trial approval for the innovative drug HSK45030 dispersible tablet
- Huaxin Cement Terminates Overseas Subsidiary Spin-Off Plan
- AAR (AIR) Following First Quarter Growth, Is The Valuation Case Still Intact?
- The Town of Frisco, CO and The NHP Foundation (NHPF) Break Ground on Landmark Middle Income Housing Development
- Ardian, Rockfield acquire majority stake in Social Hub Berlin student housing asset near Alexanderplatz
- Tempus publishes investor deck on planned Personalis acquisition to expand MRD testing platform
- Symbotic (SYM) Q3 2026 Earnings Call Transcript
- Hako San Café & Bar Coming to Downtown Kirkland
- Waterton Acquires 453-Unit City Walk at Woodbury in MN
- How Is Huntington Ingalls Industries Stock Performance Compared to Other Aerospace and Defense Stocks?
- Zhitong Finance App News, Yipinhong (300723.SZ) issued an announcement. On July 31, 2026, the company's wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical Co., Ltd. (hereinafter referred to as “Yipinhong Pharmaceutical”) and Guangzhou Lianrui Pharmaceutical Co., Ltd. (hereinafter referred to as “Lianrui Pharmaceutical”) participated in the bidding process for the 12th batch of centralized national drug procurement organized by the State Organization Drug Joint Procurement Office. Yipinhong Pharmaceutical used injectable isaconazole sulfate and Lianrui Pharmaceuticals to pass the consistent evaluation of generic drug quality and efficacy. Ammonia chloride Horizon Film (III) plans to win the bid for this centralized procurement.
- Lexington Homes to Build 53 Townhomes in Chicago’s North Shore
- AiRWA gets Nasdaq deficiency notice over late 2026 Form 10-K filing
- OmicsBank Raises $2.25M to Expand Clinical Data Infrastructure Globally for Healthcare, Life Sciences, and Frontier AI Labs
- Bullish releases September 2026 monthly metrics
- Coca-Cola sets third-quarter 2026 earnings release, investor call
- Newell Brands (NWL) Stock Jumps As Dividend Strain Clouds Turnaround
- Uber Ads: The Hidden Gem Powering Uber's Next Growth Engine
- Davidson Kempner Capital Management LP : Form 8.3 - DCC Plc
- Vermiculus Launches AI-Powered, Configurable Corporate Action System
- Ares Lands $69.4M Loan to Convert Old Charlotte School into Rental Community
- PCCP Joint Venture Plans 237-Unit BTR Development in Indianapolis
- argenx Receives Health Canada Approval For VYVGART SC As Monotherapy In Adults With Active Chronic Inflammatory Demyelinating Polyneuropathy
- Thranekær acquires Copenhagen renovation engineer Peter Jahn & Partnere
- HONDA CENTER KICKS OFF 2026-27 SEASON WITH EXCITING NHL SCHEDULE, HIGHLY ANTICIPATED CONCERTS, NEW FOOD & BEVERAGE, AND CONTINUED ARENA UPGRADES AHEAD OF OCVIBE OPENING SPRING 2027
- Itochu takes minority stake in AI drug discovery firm Molcure
- Aimbridge Hospitality Assumes Management of The Westin Cincinnati, Named Future Operator of Portman’s Cincinnati Downtown Marriott
- Merchants Capital Secures $98M for VA Affordable Development
- Plymouth Waterfront Hotel Set for Renovations
- RTX Stock And 2 Aerospace Picks Backed By Long Term Government Demand
- Webull Announces 2026 General Meeting of Shareholders and Record Date
- Amazon Eyes $8 Billion Nvidia Chip Sale to Investors as AI Infrastructure Costs Surge: Report
- Why Fund Managers Now Fear AI Capex More Than Iran, Tariffs, or a Recession
- Siemens Mobility, DLR sign rail R&D partnership deal at InnoTrans 2026
- Vantor Appoints Will Cocos to Lead U.S. Government Business
- IPO News | Excellent Vision plans to reach a valuation of US$3 billion for its Hong Kong IPO as soon as this year
- Verb Technology (VERB) Is Down 12.5% After $558M Toncoin Pivot and New Leadership Shift—Has the Bull Case Changed?
- Altair Global Relocation wins EcoVadis Silver medal, ranks top 15% on sustainability scorecard
- JLL Arranges Sale of Two Twin Cities Seniors Housing Properties
- Qianjin Pharmaceutical announced that the company plans to purchase 28.92% of the shares of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% of the shares of Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through the issuance of shares and cash payment. On September 12, 2025, the company received the “Approval to Register the Issuance of Shares by Zhuzhou Qianjin Pharmaceutical Co., Ltd. to purchase assets” from the China Securities Regulatory Commission, which agreed that the company would issue 51.44,900 shares to specific targets to purchase related assets. The purchase of assets through this issuance of shares shall be carried out in strict accordance with the relevant application documents submitted to the Shanghai Stock Exchange and completed within 12 months.
- The HKSAR Government's total housing supply target for the next ten years is 420,000 units
- OmicsBank raises $2.25 million seed round led by Redesign Health; Orbit backed 2025 pre-seed
- Hainan Mining announced that on March 12, 2025, the shareholders' meeting passed a repurchase bill, which plans to repurchase shares for 75 million yuan to 150 million yuan, with a repurchase period of 12 months. Due to the distribution of equity, the maximum repurchase price was adjusted to 14.26 yuan/share. In November, the company repurchased a total of 283,500 shares through centralized bidding transactions, accounting for 0.014% of the total share capital, and paid 2,928,800 yuan. As of the disclosure date of the announcement, a total of 346,600 shares had been repurchased, accounting for 0.017% of the total share capital. 3,4296 million yuan had been paid, and the repurchase price was 7.91 yuan/share to 11.91 yuan/share.
- Cellbion wins South Korea IND clearance for phase 3 prostate cancer trial of Lu-177 DGUL
- Update: Market Chatter: Telefónica Said to Resume Takeover Talks for Zegona's Vodafone Spain
- On September 17, according to Douyin Group, Douyin added a new “fraudulent use of voice” reporting portal under the “infringement of rights” report type, and an exclusive channel for voice infringement rights protection was launched. From now on, individual and business users can file complaints on the PC through the Douyin batch infringement reporting website, which supports two evidentiary methods: voice entry verification or uploading an original audio video.
- Dwight Arranges Construction Loan for Amarillo Apartments
- Family Caregiver Benefit Altering The Investment Case For Genworth Financial (GNW)?
- Toll Brothers Announces New Luxury Home Community Coming Soon to Apex, North Carolina
- CCO Expands Proven Industrial Platform to Address Urgent Defense Production Needs
- Hengrui Pharmaceutical (01276): Drug marketing license application for injectable Ruikang luzetotamab was accepted by the State Drug Administration
- China Tower FY26 1H profit attributable to owners jumps 30.1% to RMB 7.49 billion; revenue falls 1.8% to RMB 48.69 billion
- Gilbane Building 308 Raleigh Student Housing Units
- JIC Ventures joins HTG Medical pre-seed round, invests EUR 450,000
- Octopus Fleet launches FleetBoost to cut commercial EV public charging costs by up to 30%
- FRP, Woodfield Begin Work on Expansive Estero Development
- Hisco announced that the subsidiary Tibet Hisco Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. HSK45030 dispersible tablets are an oral, selective targeted small molecule inhibitor independently developed by the company and intended for muscular dystrophy. According to the requirements for chemical drug registration classification in the notice issued by the State Drug Administration on the “Registration Classification of Chemical Drugs and Application Data Requirements”, this product is a chemical drug category 1. Preclinical research results show that HSK45030 can effectively block the cascade of loss of muscle function, prevent long-term fibrosis and adipose tissue accumulation due to contraction-induced damage, and has shown excellent anti-muscular atrophy efficacy in animal models. It also shows good tolerability and a large safety window. It is a drug with great development potential, which is expected to provide new treatment options for patients with muscular dystrophy.
- Mohammed Malik, Executive Director of the State Bank of Pakistan: Pakistan has a complete regulatory system to support the use and investment of RMB.
- General Dynamics' GDIT Wins $1.3B Army National Guard IT And Cybersecurity Contract
- Dorman SVP, CIO Donna Long sells 734 shares for $99,225.14
- Synthesia launches Syren AI video creation tool in beta
- Zhitong Finance App News, Yipinhong (300723.SZ) issued an announcement. Guangzhou Lianrui Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration for the dry suspension of etrapopa ethanolamine. This time, the company obtained an etrapopa ethanolamine dry suspension registration certificate, indicating that the company is qualified to sell drugs of this specification in the domestic market, which will further enrich the company's product pipeline and product categories, and enhance the company's core competitiveness.
- WEALTHFRONT REPORTS SEPTEMBER 2026 MONTHLY METRICS
- Bender Companies buys 198-unit Woodland North Apartments in Minnesota
- International Tower Hill Mines Appoints David Wiens As CEO And Shane Parrow As COO, Effective August 17 And July 27, Respectively